Oruka Therapeutics (ORKA) Fundamental Analysis: Revenue, Earnings & Valuation

2.26 / 10

Underperform

The company's fundamentals score poorly at 2.3/10. While Profit-MV and Cash-MV are positive, key areas such as Net profit / Total profit (%) and Asset-MV are negative, signaling inventory and asset inefficiencies. This supports a constrained investment stance despite some redeeming factors like a healthy Inventory turnover ratio.

Analysis Checks(5/10)

Revenue-MV

Value-0.26

Score1/3

Weight14.39%

1M Return5.20%

Inventory turnover ratio

Value47.85

Score3/3

Weight12.64%

1M Return5.26%

Gross profit margin (%)

Value36.70

Score1/3

Weight-1.11%

1M Return-0.54%

Profit-MV

Value0.46

Score2/3

Weight21.54%

1M Return7.79%

PB-ROE

Value0.37

Score1/3

Weight19.89%

1M Return7.02%

Current assets turnover ratio

Value1.78

Score2/3

Weight2.52%

1M Return1.15%

Fixed assets turnover ratio

Value7979.42

Score3/3

Weight1.84%

1M Return0.86%

Asset-MV

Value-0.50

Score0/3

Weight7.36%

1M Return2.94%

Cash-MV

Value-0.07

Score2/3

Weight21.57%

1M Return7.73%

Net profit / Total profit (%)

Value100.00

Score0/3

Weight-0.64%

1M Return-0.30%

Is ORKA fundamentally strong?

ORKA scores 2.26/10 on fundamentals and holds a Premium valuation at present. Backed by its -17.46% ROE, 0.00% net margin, -16.00 P/E ratio, 3.29 P/B ratio, and 111.51% earnings growth, these metrics solidify its Underperform investment rating.